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study question: Do uric acid levels across the menstrual cycle show associations with endogenous estradiol (E2) and reproductive
hormone concentrations in regularly menstruating women?
summary answer: Mean uric acid concentrations were highest during the follicular phase, and were inversely associated with E2 and
progesterone, and positively associated with FSH.
what is known already: E2 may decrease serum levels of uric acid in post-menopausal women; however, the interplay between
endogenous reproductive hormones and uric acid levels among regularly menstruating women has not been elucidated.
study design, size, duration: The BioCycle study was a prospective cohort study conducted at the University at Buffalo re-
search centre from 2005 to 2007, which followed healthy women for one (n ¼ 9) or 2 (n ¼ 250) menstrual cycle(s).
participants/materials, setting, methods: Participants were healthy women aged 18–44 years. Hormones and uric
acid were measured in serum eight times each cycle for up to two cycles. Marginal structural models with inverse probability of exposure
weights were used to evaluate the associations between endogenous hormones and uric acid concentrations.
main results and the role of chance: Uric acid levels were observed to vary across the menstrual cycle, with the lowest
levels observed during the luteal phase. Every log-unit increase in E2 was associated with a decrease in uric acid of 1.1% (b ¼ 20.011; 95%
confidence interval (CI): 20.019, 20.004; persistent-effects model), and for every log-unit increase in progesterone, uric acid decreased by
0.8% (b ¼ 20.008; 95% CI: 20.012, 20.004; persistent-effects model). FSH was positively associated with uric acid concentrations, such
that each log-unit increase was associated with a 1.6% increase in uric acid (b ¼ 0.016; 95% CI: 0.005, 0.026; persistent-effects model).
Progesterone and FSH were also associated with uric acid levels in acute-effects models. Of 509 cycles, 42 were anovulatory (8.3%).
Higher uric acid levels were associated with increased odds of anovulation (odds ratio 2.39, 95% CI: 1.25, 4.56).
limitations, reasons for caution: The change in uric acid levels among this cohort of healthy women was modest, and
analysis was limited to two menstrual cycles. The women in this study were healthy and regularly menstruating, and as such there were
few women with high uric acid levels and anovulatory cycles.
wider implications of the findings: These findings demonstrate the importance of taking menstrual cycle phase into
account when measuring uric acid in premenopausal women, and confirm the hypothesized beneficial lowering effects of endogenous E2
on uric acid levels. These findings suggest that there could be an underlying association affecting both sporadic anovulation and high uric
acid levels among young, regularly menstruating women. Further studies are needed to confirm these findings and elucidate the connection
between uric acid and reproductive and later cardiovascular health.
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Introduction
Uric acid is a heterocyclic compound that is created when the body
breaks down purine nucleotides. About 70% of daily uric acid excre-
tion occurs via the kidneys, and in 5–25% of humans impaired renal
excretion leads to hyperuricemia. Hyperuricemia has been associated
with acute and chronic diseases, including gout, cardiovascular disease
and type 2 diabetes, though these associations are typically observed
among men and post-menopausal women (Hayden and Tyagi, 2004;
Goodson and Solomon, 2007; Darmawan, 2008; Dehghan et al.,
2008; Feig et al., 2008). It has been hypothesized that estradiol (E2)
may affect serum levels of uric acid through mechanisms involving
renal clearance, secretion and reabsorption (Puig et al., 1986;
Yahyaoui et al., 2008). However, the interplay between endogenous
reproductive hormones and uric acid levels in premenopausal
women has not been elucidated.
During the normal menstrual cycle, there are predictable and
marked changes in the hormones produced by the pituitary (LH and
FSH) and the ovary (E2 and progesterone) due to a complex system
of positive and negative feedback, which in turn affect the process
of ovulation (Hall, 2011). Endogenous sex hormones contribute to
the overall physiological health of premenopausal women and fluctua-
tions in these hormones beyond the normal range have been linked
to variations in several known risk factors for cardiovascular disease,
including cholesterol, insulin, F2-isoprostanes and high sensitivity
C-reactive protein (Gaskins et al., 2010; Mumford et al., 2010;
Schisterman et al., 2010; Yeung et al., 2010). Elevated uric acid is
another known risk factor for cardiovascular disease among men
and post-menopausal women, though its variability across the men-
strual cycle in premenopausal women has not been established
(Hayden and Tyagi 2004; Goodson and Solomon, 2007; Darmawan,
2008; Feig et al., 2008).
The objectives of this study were to characterize variability of uric
acid levels across the menstrual cycle and evaluate the associations
between endogenous serum hormone concentrations and ovulation
with uric acid levels in a cohort of young, regularly menstruating
women. Based on prior research in similar cohorts (Pucher et al.,
1933; Adamopoulos et al., 1977; Wingrove et al., 1998), our
primary hypothesis was that E2 would decrease both acute (measured




The BioCycle study was a prospective cohort of 259 regularly menstruat-
ing, healthy female volunteers, aged 18–44 years, recruited from the
western region of NY, USA. Details of the study design and screening
process are described elsewhere (Wactawski-Wende et al., 2009). In
brief, exclusion criteria included the current use of oral contraceptives
(or use during the previous three months) and diagnosis of certain
chronic conditions, including history of menstrual and ovulation disorders
or clinical signs or history of gynecological problems. Further, women with
a history of polycystic ovary syndrome (PCOS) were also excluded.
Women with a self-reported BMI of ,18 or .35 kg/m2 at screening
were also excluded. The University at Buffalo Health Sciences Institutional
Review Board (IRB) approved the study, and served as the IRB designated
by the National Institutes of Health for this study under a reliance agree-
ment. All participants provided written informed consent.
Participants were followed for one or two menstrual cycles with blood
samples collected for hormonal and uric acid assessment during the fol-
lowing phases: second day of menstruation; mid-follicular; late follicular;
LH/FSH surge; predicted ovulation; early luteal; mid-luteal and late
luteal phase. Fertility monitors (Clearblue Easy Fertility Monitor; Inverness
Medical, Waltham, MA, USA) were used to assist with the timing of spe-
cimen collection (Howards et al., 2009). Fertility monitors measured
estrone-3-glucuronide and LH in urine, starting on calendar day 6 after
menses and continuing for 10–20 days, depending on whether the
woman reached peak levels on the monitor. Monitor indications of low,
high and peak fertility were used to time mid-cycle visits, with other
visits scheduled according to an algorithm that took each woman’s
reported cycle length into consideration (Mumford et al., 2011a).
Women were highly compliant with the study protocol, with 94% of
women completing at least seven of eight clinic visits per cycle.
Hormone, uric acid and ovulation assessment
Reproductive hormones and uric acid were measured in serum using
fasting blood samples collected at each cycle visit (eight visits per cycle).
All samples were frozen at 2808C and sent as complete participant
cycle batches for hormone analysis to reduce batch variability (Kaleida
Health Center for Laboratory Medicine, Buffalo, NY, USA). E2, FSH, LH
and progesterone were measured using solid-phase competitive chemilu-
minescent enzymatic immunoassays by Specialty Laboratories, Inc. (Valen-
cia, CA, USA) on the DPC Immulite 2000 analyzer (Siemens Medical
Solutions Diagnostics, Deerfield, IL, USA). Uric acid was measured using
a Beckman LX20 autoanalyzer and employing a uricase methodology
coupled to the production of hydrogen peroxide. Across the study
period the inter-assay coefficient of variation for these tests reported by
the laboratory was ,10% for E2, ,5% for LH and FSH, ,14% for pro-
gesterone and ,3% for uric acid. Cycles were defined as anovulatory if
peak progesterone concentrations were ≤ 5 ng/ml (Legro et al. 2007;
Diamanti-Kandarakis et al., 2009) across the cycle and no serum LH
peak was observed during the later cycle visits (42 of 509 cycles (8.3%)).
Covariate assessment
At study enrollment, BMI was obtained using standardized protocols by
trained study staff, while age, race, smoking, physical activity, lifestyle,
health and reproductive history were obtained using validated question-
naires (Craig et al., 2003; Wactawski-Wende et al., 2009). Cycle length
was defined as the number of days from the first day of bleeding
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(menstruating by 1600 h) until the day before the next onset of bleeding
after confirming 2 consecutive days of bleeding, to differentiate from spot-
ting. Day of ovulation in ovulatory women was assigned based on dates
and levels of the LH peak using the fertility monitor compared with the
observed LH maximum value in serum and the first day of progesterone
rise. Follicular phase length was defined as Day 1 of bleeding to the day
of ovulation. Luteal phase length was defined as ovulation through the
last day of the cycle. No covariate was missing for .5% of women.
Dietary intake was assessed using a 24-h dietary recall conducted four
times/cycle corresponding to menstruation, mid-follicular phase, ovulation
and mid-luteal phase (Nutrition Data System for Research software
version 2005, Nutrition Coordinating Center, University of Minnesota,
Minneapolis, MN, USA). The majority of cycles had complete dietary
recall information (87% of cycles with four recalls per cycle).
Statistical analysis
Descriptive statistics were calculated for demographic characteristics and
dietary intake. Fisher’s exact test and analysis of variance were used to
test for associations between demographic variables and tertiles of
mean uric acid levels (mean of uric acid levels across up to 16 visits per
woman). Based on previous studies, we further defined a woman as
hyperuricemic if her uric acid levels were .6 mg/dl (Nagahama et al.,
2004; Freid and Smith, 2007; Darmawan, 2008; Feig et al., 2008). Cycle
length, luteal phase length, percentage of women with short luteal phase
lengths (,12 days) and mean hormone levels across the cycle were com-
pared between tertiles of mean uric acid levels (mean of uric acid levels
across up to eight visits per woman per cycle). Uric acid levels were
also compared between women with luteal phase lengths ,12 versus
≥12 days. In addition, changes in uric acid, E2 and progesterone concen-
trations were calculated separately for ovulatory and anovulatory cycles,
and were subsequently analyzed and compared across all phases of the
menstrual cycle, as well as collapsed by follicular and luteal phases.
P-values were calculated for each pairwise between-visit comparison.
Marginal structural models with inverse probability of exposure weights
were used to estimate associations between log hormone levels and log
uric acid levels measured on the same day (acute effects) or between
log hormone levels at one visit predicting log uric acid levels at the next
visit (persistent effects) (Robins et al., 2000; Cole and Hernan, 2008).
Persistent-effects models represent prolonged exposure to hormones
(2 days; range 1–5 days) and were used to establish temporality of
effects. Weighted linear mixed effect models with random intercepts
were used to estimate the parameters of the marginal structural model,
allowing both uric acid and hormone levels to vary over time (Robins
et al., 2000; Cole and Hernan, 2008). Random-intercept models were
used to account for the variation in baseline hormone concentrations
between women and the correlation between visits of the same
woman. Stabilized inverse probability of exposure weights for each cycle
visit were obtained by ordinal logistic regression with the exposure cate-
gorized in deciles to decrease unnecessary variability in the weights, and
were adjusted for age, BMI, race and other reproductive hormones. For
example, models to calculate the weights for E2 included age, BMI, race,
FSH, LH and progesterone, as well as past measurements of E2.
Weights for the other hormones were calculated in a similar manner. Add-
itional measures of dietary intake, physical activity, smoking, alcohol use
and race were considered as potential covariates but did not appreciably
alter the estimates. The mean (range) of the stabilized weights for the
acute models were 1.00 (0.13, 10.92) for E2, 0.99 (0.13, 3.55) for proges-
terone, 1.00 (0.03, 27.64) for LH and 0.99 (0.01, 35.99) for FSH (values
were similar for persistent models). Results were similar when truncating
the weights at the 1st and 99th percentile. Scatter plots of log transformed
hormone and uric acid concentrations, with data points sized
proportionally to the inverse probability weights are shown to display
the relative contributions of each individual in the study, along with the
weighted regression line from the unadjusted acute effects models and a
lowess smoothed regression line to demonstrate linearity of associations
(results correspond to regression model results). Uric acid and hormone
levels were allowed to vary over time, and all models included hormone
and uric acid concentrations throughout the cycle, including up to eight
measurements per cycle. As changes in hormones represent cyclic
changes and are the result of complex feedback mechanisms, we utilized
this marginal structural modeling approach to specifically address this
type of time-varying confounding. This approach enables evaluation of
the change in the uric acid level for each increase in E2, after adjustment
for progesterone and FSH levels, for example.
Generalized estimating equations were used to model the association
between mean uric acid levels across each cycle and the odds of anovula-
tion while adjusting for age, race and BMI. Models were additionally run to
evaluate the association between uric acid levels during each phase of
the menstrual cycle and the probability of anovulation. SAS version 9.2
(SAS Institute, Cary, NC, USA) was used for all statistical analyses.
A P , 0.05 was considered significant.
Results
Demographics
Overall, women in the BioCycle study were young (mean age: 27.3
years), of healthy weight (mean BMI: 24.1), physically active (moderate
to high physical activity: 90%), non-smokers (96%) and of white (59%)
and black (20%) race (Table I). Mean levels of uric acid varied signifi-
cantly according to age and BMI, with lower mean levels of uric acid
observed among older and thinner women within this cohort of
young healthy women of reproductive age. In addition, women with
higher uric acid levels tended to have experienced at least one an-
ovulatory cycle. Physical activity, dietary animal protein and average
alcohol intake were not significantly associated with uric acid. Only a
small number of women were hyperuricemic at any given point in a
cycle (uric acid ≥6 mg/dl; n ¼ 20 women). Only 10 of these
women had high levels on more than one visit. In particular, seven
women had high levels on Day 2 (1.4%), five during the mid-follicular
phase (1.0%), two during late follicular (0.4%), three during the
LH/FSH peak visit (0.6%), four during predicted ovulation (0.8%),
six during early luteal (1.2%), six during mid-luteal (1.2%) and three
during the late luteal phase (0.6%) (women had high levels at more
than one visit).
Cycle length and luteal phase length were not significantly associated
with uric acid levels (Table II). However, cycles with high mean uric acid
concentrations across the cycle were more likely to be anovulatory
(Tertile 3 versus Tertile 1: 14.0 versus 4.7%; P ¼ 0.007), and more
likely to have shorter luteal phases though this was not statistically signifi-
cant (Tertile 3 versus Tertile 1: 13.7 versus 6.4; P ¼ 0.11). Mean E2 and
progesterone levels were lower among women in the highest tertile of
mean uric acid levels (Table II).
Uric acid variability across the menstrual
cycle
Uric acid levels peaked during the follicular phase, dropped around
ovulation and further declined during the luteal phase (Fig. 1). Specif-
ically, mean uric acid levels decreased by 1.9% (means: 4.21 versus
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Table I Characteristics of women participating in the BioCycle study (259 women) according to the mean serum uric acid
level, BioCycle study, Buffalo, NY 2005–2007.
Mean serum uric acid (tertiles)a P-valueb






n (number of women)c 259 83 91 85
Demographics
Mean (SD)
Age, years 27.3 (8.2) 29.6 (8.6) 27.2 (8.3) 25.1 (7.2) 0.002
Age at menarche, years 12.5 (1.2) 12.4 (1.2) 12.4 (1.1) 12.5 (1.4) 0.97
BMI, kg/m2 24.1 (3.9) 23.2 (3.4) 23.7 (3.7) 25.4 (4.2) 0.0004
n (%)
Race
White 154 (59) 46 (55) 55 (60) 53 (62) 0.71
Black 51 (20) 20 (24) 18 (20) 13 (15)
Other 54 (21) 17 (21) 18 (20) 19 (22)
≤High school education 33 (13) 12 (14) 9 (10) 12 (14) 0.60
Married 66 (25) 26 (31) 22 (24) 18 (21) 0.31
Nulliparousd 187 (74) 55 (67) 69 (78) 63 (77) 0.26
Current smoker 10 (4) 1 (1) 4 (4) 5 (6) 0.31
Physical activity
Low 25 (10) 10 (12) 6 (7) 9 (11) 0.28
Moderate 92 (35) 35 (42) 31 (34) 26 (31)
High 142 (55) 38 (46) 54 (59) 50 (59)
Ever sexually actived 192 (75) 69 (84) 63 (70) 60 (72) 0.07
Currently sexually activee 135 (70) 47 (68) 47 (75) 41 (68) 0.66
Past OC used 140 (55) 53 (65) 48 (53) 39 (47) 0.07
At least one anovulatory cyclef 35 (14) 7 (8) 8 (9) 20 (24) 0.007
Ovulatory cycle groupg
Two ovulatory cycles 219 (88) 75 (93) 81 (91) 63 (79) 0.03
One ovulatory and one anovulatory cycle 24 (10) 6 (7) 5 (6) 13 (16)
Two anovulatory cycles 7 (3) 0 (0) 3 (3) 4 (5)
Dietary variablesh
Mean (SD)
% Total energy from carbohydrates 50.8 (7.1) 51.6 (6.8) 50.8 (7.7) 50.1 (6.8) 0.38
% Total energy from protein 15. (2.9) 15.5 (2.8) 15.8 (3.1) 15.9 (3.0) 0.62
% Total energy from fat 33.9 (5.4) 33.5 (5.0) 33.7 (5.9) 34.5 (5.3) 0.45
% Total energy from alcohol 1.0 (2.0) 1.0 (2.0) 1.1 (2.2) 1.0 (1.6) 0.86
Total energy, kcal 1607.4 (354.3) 1625.7 (396.9) 1575.4 (305.1) 1624.0 (361.1) 0.56
Total fat, g 62.1 (18.5) 61.9 (18.6) 60.9 (18.1) 63.7 (19.1) 0.59
Alcohol, g 2.7 (5.2) 2.7 (5.6) 2.8 (5.7) 2.5 (4.0) 0.96
Fructose, g 16.9 (9.0) 17.9 (10.1) 15.7 (8.1) 17.3 (8.8) 0.24
Total protein, g 62.2 (15.6) 61.7 (17.6) 61.6 (14.2) 63.4 (15.1) 0.69
Animal protein, g 40.7 (14.4) 39.4 (15.3) 40.3 (13.4) 42.3 (14.7) 0.39
Total cholesterol, mg 209.8 (98.0) 204.1 (95.3) 205.5 (92.3) 220.1 (106.6) 0.50
OC, oral contraceptives; UA, uric acid.
aWomen were categorized according to tertile of mean uric acid levels across all 16 study visits.
bTwo-sided P-values for continuous variables calculated using analysis of variance (ANOVA), and for categorical variables using Fisher’s exact test.
c250 women in the BioCycle study were followed for two cycles, nine women were followed for one cycle, for a total of 509 cycles.
dFor six women information was missing on parity, and for four women information was missing on past OC use and if ever sexually active.
ePercentages calculated from the 192 women reporting ever being sexually active.
fTwenty-eight women in the study had only one anovulatory cycle, and seven women in the study had two anovulatory cycles for a total of 35 women with at least one anovulatory
cycle. There were a total of 42 anovulatory cycles out of a total 509 in the BioCycle study.
gOnly includes 250 women with two cycles under study.
hIndicates the mean of the within-woman average of all 24-h recall measurements across the study.
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4.14 mg/dl; P ¼ 0.09) from the mid-follicular phase to around ovula-
tion, by 2.4% (means: 4.21 versus 4.11 mg/dl;P ¼ 0.04) at the
mid-luteal phase and by 3.9% (means: 4.21 versus 4.05 mg/dl; P ¼
0.001) at the late luteal phase. However, the mean change within a
cycle was much greater [30% change; range, 6–139%; mean change
(SD), 1.1 (0.5) mg/dl]. In addition, uric acid levels were higher
among anovulatory than ovulatory cycles during both the follicular
(P ¼ 0.0008) and luteal phases (P ¼ 0.0002), and tended to be
higher during the follicular than the luteal phase of ovulatory cycles,
although this difference was not statistically significant (P ¼ 0.38)
(Table III and Fig. 1). These changes correspond to higher E2 and pro-
gesterone levels during ovulatory cycles, especially during the luteal
phase (Table III).
Sex hormones
Overall, E2 and progesterone were inversely associated with uric acid
levels across the menstrual cycle, with the persistent effects being
stronger (Table IV, Fig. 2). In acute effects models, after adjusting
for age, race, BMI and other hormones, E2 was not significantly
........................................................................................................
.............................................................................................................................................................................................
Table II Characteristics of menstrual cycles according to the mean serum uric acid levels.
Mean serum uric acid (tertiles)a P-valueb






n (number of cycles)c 509 171 173 165
Anovulatoryd 42 (8.3) 8 (4.7) 11 (6.4) 23 (14.0) 0.007
Cycle length, days 28.8 + 4.1 28.4 + 4.1 29.1 + 3.7 28.9 + 4.5 0.32
Luteal phase length, days 13.9 + 2.4 13.8 + 1.7 14.2 + 2.3 13.9 + 3.0 0.31
Luteal phase ,12 d, n (%) 41 (9.3) 10 (6.4) 13 (8.3) 18 (13.7) 0.11
Uric acid (mg/dl) levels for luteal phase ,12 days 4.35 + 0.64 3.51 + 0.31 4.18 + 0.18 4.93 + 0.30 0.97
Uric acid (mg/dl) levels for luteal phase ≥12 days 4.08 + 0.65 3.44 + 0.35 4.10 + 0.18 4.88 + 0.36
Mean estradiole (pg/ml) 112.0 + 43.4 114.0 + 41.4 116.4 + 44.5 105.4 + 43.6 0.05
Mean progesterone (ng/ml) 3.4 + 1.8 3.7 + 1.7 3.6 + 1.7 3.0 + 1.8 0.0004
Mean LH (ng/ml) 9.5 + 3.6 9.1 + 3.5 9.7 + 3.6 9.8 + 3.8 0.21
Mean FSH (mIU/ml) 6.4 + 2.4 6.7 + 2.8 6.2 + 1.8 6.3 + 2.4 0.09
aWomen were categorized according to tertile of mean uric acid levels across all 16 study visits.
bTwo-sided P-values for continuous variables calculated using repeated measures ANOVA, and for categorical variables using Fisher’s exact test. All comparisons take repeated
measures and correlations between cycles into account.
c250 women in the BioCycle study were followed for two cycles, nine women were followed for one cycle, for a total of 509 cycles.
dTwenty-eight women in the study had only one anovulatory cycle, and seven women in the study had two anovulatory cycles for a total of 35 women with at least one anovulatory
cycle. There were a total of 42 anovulatory cycles out of a total 509 in the BioCycle study.
eIndicates the mean of the within-woman average of all hormone measurements.
Figure 1 Geometric mean uric acid levels with 95% CIs, and geometric mean estradiol and progesterone levels across phases of the human men-
strual cycle by ovulatory status (left: ovulatory; right: anovulatory).
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associated with uric acid levels (b ¼ 20.005, 95% confidence interval
(CI): 20.012, 0.002). In persistent-effects models, for every log-unit
increase in E2, uric acid decreased by 1.1% (b ¼ 20.011, 95%
CI: 20.019, 20.004). For every log-unit increase in progesterone
(an increase of 2 log units was observed between the follicular
and luteal phases), uric acid decreased by 0.6% (b ¼ 20.006,
95% CI: 20.010, 20.002) in acute-effects models and by 0.8%
(b ¼ 20.008, 95% CI: 20.012, 20.004) in persistent-effects models.
FSH concentrations were associated with uric acid levels in both
acute and persistent models, where each log-unit increase in FSH
was associated with a 1.7% increase in uric acid in both models
(Table IV, Fig. 2). No associations were observed between LH
concentrations and uric acid.
Anovulation
Results from a generalized estimating equations model adjusting for
age, race and BMI showed that for each mg/dl increase in mean
uric acid levels over the cycle, the adjusted odds ratio of anovulation
was 2.39 (95% CI: 1.25, 4.56; Table IV). Thus, each mg/dl increase in
uric acid was associated with a 139% elevation in the odds of
.............................................................................................................................................................................................
Table III Hormone and uric acid levels by cycle phase overall and by ovulatory status.
Total cohort Ovulatory cycles Anovulatory cycles P (ovulatory versus
anovulatory)
n (number of cycles) 509 467 42
Uric acida (mg/dl)
Follicular phase 4.16+0.69 4.13+0.68 4.50+0.62 0.0008
Luteal/premenstrual phase 4.12+0.65 4.09+0.64 4.47+0.58 0.0002
P (follicular versus luteal) 0.37 0.38 0.86
Estradiol (pg/ml)
Follicular phase 102.5+51.7 105.9+51.8 64.4+32.4 ,0.0001
Luteal/premenstrual phase 122.1+54.7 125.2+53.9 87.5+51.3 ,0.0001
P (follicular versus luteal) ,0.0001 ,0.0001 0.02
Progesterone (ng/ml)
Follicular phase 0.9+1.0 1.0+1.0 0.7+0.4 0.04
Luteal/premenstrual phase 6.1+3.2 6.6+3.0 1.3+0.8 ,0.0001
P (follicular versus luteal) ,0.0001 ,0.0001 ,0.0001
aThe mean uric acid, estradiol and progesterone levels were calculated for each woman overall and by phase for each cycle under study.
................................................ ...................................................
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Table IV Associations between serum concentrations of menstrual hormones and uric acid levels.
Log hormone Modela Acute: uric acid (mg/dl) Persistent: uric acid (mg/dl)
b 95% CI b 95% CI
Estradiol (pg/ml) Model 1 20.012 20.020, 20.005* 20.017 20.025, 20.010**
Model 2 20.006 20.013, 0.0008 20.011 20.018, 20.004*
Model 3 20.005 20.012, 0.002 20.011 20.019, 20.004*
Progesterone (ng/ml) Model 1 20.007 20.011, 20.003* 20.008 20.013, 20.004*
Model 2 20.006 20.010, 20.002* 20.008 20.012, 20.003*
Model 3 20.006 20.010, 20.002* 20.008 20.012, 20.004*
FSH (mIU/ml) Model 1 20.004 20.014, 0.006 0.0009 20.009, 0.011
Model 2 0.016 0.006, 0.025* 0.021 0.011, 0.031**
Model 3 0.017 0.007, 0.028* 0.016 0.005, 0.026*
LH (ng/ml) Model 1 0.006 20.0004, 0.013 0.007 0.0002, 0.014*
Model 2 0.004 20.002, 0.010 0.004 20.002, 0.011
Model 3 0.002 20.006, 0.010 0.005 20.002, 0.012
Odds ratio 95% CI
Anovulatory Model 1 2.42 1.47, 4.00*
Model 2 2.39 1.25, 4.56*
b, effect estimate; CI, confidence interval.
aModel 1: unadjusted; Model 2: adjusted for age, race, and body mass index; Model 3: adjusted for age, race, BMI, and other reproductive hormones through the use of inverse
probability of exposure weights. Models for hormones obtained using weighted linear mixed models and for anovulation using generalized linear mixed models.
*P-value ,0.05, **P-value ,0.0001.
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anovulation (less likely to ovulate). Uric acid levels during each phase
of the menstrual cycle were associated with increased odds of anovu-
lation (data not shown).
Discussion
Uric acid levels were highest during the follicular phase and declined
during the luteal phase. Increased levels of endogenous E2 were asso-
ciated with decreased uric acid concentrations in persistent-effects
models only, and progesterone was associated with decreased uric
acid concentrations in both acute- and persistent-effects models. In
addition, increased uric acid levels were associated with increased
odds of sporadic anovulation in this cohort of young, regularly men-
struating women. This is the first study to use multiple measurements,
timed to key periods of hormonal variability, over the course of the
menstrual cycle to evaluate both the acute and persistent effects of re-
productive hormones on uric acid. Previous studies among premeno-
pausal women were not well timed to menstrual cycle phase
(Adamopoulos et al., 1977; Anton et al., 1986; Wingrove et al.,
1998). This novel finding of an association between uric acid and ano-
vulation raises a potentially important biological pathway relating
metabolic disturbances and normal hormonal function. Thus, this
study provides important insight into the associations between sex
hormones, ovulation and uric acid among healthy women of repro-
ductive age.
Although the mean uric acid changes observed across the cycle
were modest (only 2–4% on average), the within-woman variability
was much greater (30% on average). Previous studies are limited,
though Pucher et al. (1933) assessed the variability of uric acid
across the menstrual cycle and observed similar results in two
young women; serum uric acid levels were highest during menstru-
ation and continuously fell thereafter. Of note, in the present study
the variability across the cycle was observed among healthy women
of reproductive age, further emphasizing the importance of consider-
ing menstrual cycle variability, as greater changes may be observed
among other at-risk populations (overweight/obese, women with
PCOS, etc.).
The inverse association between E2 and uric acid levels in the
persistent-effects models is consistent with past research, which has
evaluated the effects of both endogenous and exogenous E2. Never-
theless, the few studies that have evaluated premenopausal women
are small and usually compare premenopausal women with men
and post-menopausal women, rather than look at the changes in
uric acid across phases of the cycle. They also primarily look at the
acute effects of E2, and do not include any persistent effects that
take temporality into account. In one of the few studies that analyzed
the effects of endogenous E2 on uric acid, an inverse relationship
between uric acid levels and endogenous E2 was evident in three pre-
menopausal women (Adamopoulos et al., 1977). In a study among 50
premenopausal and 88 post-menopausal non-obese white women,
Figure 2 Scatter plot of log transformed hormone [(A) estrogen, (B) progesterone, (C) LH and (D) FSH] and uric acid concentrations, with data
points sized proportionally to the inverse probability weights. The black line represents the weighted regression line from the unadjusted acute effects
models (beta coefficients and 95% CIs for these models are presented in Table IV) and the red line a lowess smoothed regression line.
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Wingrove et al. (1998) observed that uric acid concentrations were
significantly higher in post-menopausal versus premenopausal
women, consistent with lower estrogen levels among post-
menopausal women. Similarly, sex differences in the renal handling
of uric acid have been observed, with women showing a significantly
lower serum urate concentration when compared with men
(studied among nine premenopausal women and nine healthy age-
matched men), although E2 treatments did not have an effect on the
renal handling of uric acid or serum urate levels among these
women (Anton et al., 1986; Puig et al., 1986). In a study comparing
post-menopausal women with and without gout, Marinello et al.
(1985) observed a significant decrease in FSH, LH and E2 in patients
with gout. Further, some studies have observed elevated uric acid
levels among women with PCOS (Anttila et al., 1996; Macut et al,
2011), although these differences were not always statistically signifi-
cant (Anttila et al., 1996). The findings of the present study extend
previous work and evaluate a larger group of healthy, premenopausal
women with visits timed to menstrual cycle phase.
Additional studies have focused on the effect of hormone therapy
(HT) on uric acid levels in both post-menopausal women and men.
In 9 post-menopausal women out of 13, the administration of conju-
gated and synthetic E2 produced a fall in the plasma uric acid concen-
tration in the same study analyzing the effects of endogenous E2 on
uric acid (Adamopoulos et al., 1977). Sumino et al. (1999) assessed
61 post-menopausal women before and during the administration of
HT and showed that treatment significantly reduced mean serum
uric acid concentrations throughout the 3–12-month study period
in post-menopausal women with hyperuricemia. Similarly, using data
from the Third National Health and Nutrition Examination Survey,
Hak and Choi (2008) observed that menopause was associated with
higher serum uric acid levels and current hormone use among
post-menopausal women to be associated with a lower serum uric
acid level. In addition to the effects of HT on post-menopausal
women, E2 therapy has also been associated with decreases in uric
acid levels among transsexual men (Nicholls et al., 1973; Yahyaoui
et al., 2008). An antiandrogenic contraceptive pill also was shown to
significantly reduce uric acid levels among women with PCOS
(Luque-Ramirez et al., 2008).
Ours is the only study to date to our knowledge that analyzed the
effects of progesterone, FSH and LH on uric acid levels, in addition to
E2. An inverse association between progesterone and uric acid levels
was observed in both acute and persistent models, which has not
been presented in the past literature, especially among women of repro-
ductive age. In this study, E2 levels were taken into account in the mar-
ginal structural models when evaluating the associations between
progesterone and uric acid levels. The effects of progesterone during
the luteal phase did not appear to be reduced because of high levels
of endogenous E2 during the luteal phase. Furthermore, uric acid
levels were lowest during the luteal phase, which corresponds to a
natural state of opposed estrogen and high progesterone concentra-
tions. Marinello et al. (1985) observed low levels of FSH in women
with gout, but did not directly model the relationship between FSH
and uric acid levels. Thus, further research in this area is warranted to
confirm our findings of a positive association between FSH and uric
acid levels after adjustment for age, race and BMI.
Biologically, the uricosuric effects of E2 are thought to take place
within the nephron. Endogenous E2 appears to decrease uric acid
levels by lowering the post-secretory tubular reabsorption of uric
acid (Puig et al., 1986; Yahyaoui et al., 2008). Based on previous
studies, renal tubular secretion of urate may greatly exceed uric acid
excretion and a large fraction of this secreted urate is reabsorbed
by the nephron (Diamond and Paolino, 1973). Thus, E2 may be affect-
ing serum levels of uric acid through mechanisms involving the fraction-
al excretion of uric acid (Yahyaoui et al., 2008). However, these
mechanisms are not fully understood as one study found that E2 treat-
ments did not have an effect on the renal handling of uric acid or
serum urate levels (Anton et al., 1986; Puig et al., 1986).
Although a number of previous studies have evaluated the associ-
ation between E2 and uric acid, similar relationships to sporadic ano-
vulation have not been widely studied in the past literature. Studies
show that women with either high uric acid concentrations or ovula-
tory disorders, such as PCOS, may be at increased risk for cardiovas-
cular disease (Legro et al., 2003; Randeva et al., 2012) but the
pathways connecting uric acid and anovulation remain unclear. The
observed association between uric acid and anovulation could be
attributed to issues in follicular development. Based on this associ-
ation, lower levels of E2, which are associated with higher uric acid,
may produce an increase in FSH levels needed to initiate feedback
mechanisms in order to compensate for impaired follicular develop-
ment. Further, as uric acid is a purine derivative and other studies
have shown that purines may inhibit oocyte maturation, this could
potentially explain the association between uric acid and sporadic ano-
vulation, alongside the increased levels of FSH (Lavy et al., 1990;
Alexiou and Leese, 1992; Downs, 1993; Wen et al., 2010). High
levels of uric acid among anovulatory women may also be indicative
of an underlying endocrine or metabolic disturbance, even among
women reporting regular menstrual cycles (Mumford et al., 2011b).
Although these mechanisms seem plausible, further studies should elu-
cidate these hypotheses more directly in women with more persistent
anovulation.
Intensive monitoring of a large number of young women, of black
and white ethnicities, throughout two menstrual cycles, with multiple
clinic visits timed with fertility monitors, are unique strengths of this
study. Multiple measurements of both hormones and uric acid
enabled more precise modeling of the association between E2 and
uric acid levels and evaluation of both acute and persistent effects.
The prospective design and exclusion criteria at baseline of the Bio-
Cycle study strengthen the ability to draw inference, having reduced
the potential for bias from known risk factors for anovulation, although
the generalizability of the findings is strictly limited to regularly cycling
women. Adjustment was made for particular dietary factors that affect
uric acid levels, such as alcohol and animal protein intake, but these
factors had no effect on the results. Collectively, these unique
aspects of the study design allowed for improvement and expansion
on previous studies of uric acid and reproductive hormones and
ovulation.
Nevertheless, the study faced limitations, which included the small
number of women with hyperuricemia (≥6 mg/dl; n ¼ 20 women)
and the small number of anovulatory cycles (n ¼ 42), which resulted
in less precise estimates than would have been ideal. In the absence
of a daily transvaginal ultrasound or daily first morning urine measure-
ments, the detection of ovulation has some degree of misclassification.
In addition, women were only followed for one or two menstrual
cycles. Younger women were more likely to have higher uric acid
1860 Mumford et al.
levels, which is unexpected because of the known increase in uric acid
levels with age (Kannel, 1987). This may be attributable to the high
percentage of anovulatory cycles and other metabolic disturbances
among the young women in this study (Mumford et al., 2011b). Fur-
thermore, overall levels of uric acid were low, which is consistent
with the fact that the women in the BioCycle study may not have
reached the age where uric acid levels are expected to increase.
Lastly, the observed associations between E2 (persistent-effects
only) and progesterone (both acute and persistent-effects) and
uric acid were small in magnitude. However, given the inter-assay vari-
ability for E2 and progesterone the observed associations may be
underestimates assuming non-differential, monotonic measurement
error.
In conclusion, we observed that uric acid levels varied across
the menstrual cycle and were inversely associated with E2 in
persistent-effects models and progesterone levels in acute and
persistent-effects models among healthy premenopausal women. In
addition, regularly menstruating women with higher serum urate
levels had a substantially higher probability of anovulatory cycles.
These data show, in contrast to the expectation that E2 played the
major role, that progesterone as well as E2 levels appear important
in suppressing uric acid levels; thus, in terms of uric acid relationships,
ovulatory cycles may play an additional role to E2 in protecting
women’s future cardiovascular health. As both hyperuricemia and
anovulation are major risk factors for disease, these findings suggest
that there could be an underlying association affecting both sporadic
anovulation and high uric acid levels among young, regularly menstru-
ating women (Hayden and Tyagi, 2004; Goodson and Solomon, 2007;
Darmawan, 2008; Dehghan et al., 2008; Feig et al., 2008). This study
demonstrates that it is important to take menstrual cycle phase into
account when measuring uric acid. Further studies are needed to
confirm these findings and elucidate the connection between uric
acid and reproductive and later cardiovascular health.
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